Medindia

X

Reportlinker Adds U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2010

Wednesday, January 13, 2010 General News J E 4
Advertisement


NEW YORK, Jan. 12 Reportlinker.com announces that a new market research report is available in its catalogue:

U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2010

http://www.reportlinker.com/p0170910/US-Market-for-Diabetes-Monitoring-Treatment-and-Drug-Delivery-2010.html

There are currently over 23.6 million people in the U.S., or almost 8% of the population who have diabetes. The diabetes market is expected to show substantial growth due to the obesity epidemic in the U.S., now becoming known as diabesity. This report covers the U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery, which includes:

- blood glucose diagnosis and monitoring including traditional blood glucose monitors

- continuous glucose monitoring systems (CGM),

- blood glucose test strips

- lancets and lancing devices

This market also includes the markets for insulin and insulin delivery devices including syringes, pens, pumps and jet injectors as well as oral anti-diabetic drugs.

Over the forecast period, the U.S. market for diabetes drugs, devices and monitoring systems is expected to grow at double-digit rates, reaching a value of over $55 billion by 2016. The market for insulin will grow over 18% in 2009, while continuous glucose monitoring systems will see growth of 48%. This report provides a comprehensive analysis of the blood glucose monitoring, insulin delivery and antidiabetic drug markets.

Within the diabetic devices market, companies such as Abbott, Bayer, Eli Lilly, Lifescan, Medtronic and Roche lead the market. This report also covers the insulin market as well as oral and injectable antidiabetic drugs. Oral drugs are estimated to see double-digit growth through 2016, with companies such as Amylin, Bristol-Myers, Squibb, GlaxoSmithKline, Merck & Co., Novo Nordisk, Pfizer and Takeda leading the market. This report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2016, unit sales, average selling prices, market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios.

TABLE OF CONTENTS ........ I

LIST OF FIGURES ........... VIII

LIST OF CHARTS ............ XIII

EXECUTIVE SUMMARY ...18

1.1 U.S. MARKET FOR DIABETES DIAGNOSIS, TREATMENT AND DRUG DELIVERY......... 18

1.2 TREND ANALYSIS BY SEGMENT .......... 19

1.3 BLOOD GLUCOSE MONITORING MARKET .................. 20

1.4 DIABETIC POPULATION .......... 21

1.5 INSULIN 22

1.6 INSULIN SYRINGES ...... 23

1.7 INSULIN PENS .............. 24

1.8 INSULIN PUMPS ........... 24

1.9 ORAL ANTIDIABETIC DRUGS . 25

1.9.1 Price Analysis ....... 25

1.9.2 Market Analysis .... 26

1.10 LEADING COMPETITORS IN THE DIABETES DEVICES MARKET ......... 27

1.11 LEADING COMPETITORS IN THE INSULIN AND ANTIDIABETIC DRUG MARKET........ 28

RESEARCH METHODOLOGY ....29

2.1 RESEARCH SCOPE ....... 29

2.2 IDATA'S 9-STEP METHODOLOGY ........ 29

Step 1: Project Initiation & Team Selection ............... 30

Step 2: Prepare Data Systems and Perform Secondary Research ....... 31

Step 3: Preparation for Interviews & Questionnaire Design 32

Step 4: Performing Primary Research . 33

Step 5: Research Analysis: Establishing Baseline Estimates 35

Step 6: Market Forecast and Analysis . 35

Step 7: Identify Strategic Opportunities ..................... 37

Step 8: Final Review and Market Release .................. 38

Step 9: Customer Feedback and Market Monitoring .. 39

OVERVIEW OF DIABETES ..........40

3.1 INTRODUCTION ........... 40

3.2 MAIN TYPES OF DIABETES .... 40

3.2.1 Type 1 Diabetes .... 40

3.2.2 Type 2 Diabetes .... 40

3.2.3 Gestational Diabetes ........ 41

3.2.4 Prediabetes ........... 41

3.3 DIABETES COMPLICATIONS ... 42

3.4 RISK FACTORS ASSOCIATED WITH TYPE 1 AND TYPE 2 DIABETES ..... 44

3.5 SIGNS AND SYMPTOMS .......... 46

3.6 MONITORING .............. 47

3.6.1 Initial Diagnosis ... 47

3.6.2 Blood Glucose Monitoring Systems ...................... 48

3.6.3 Urinary Glucose Monitoring ......... 49

3.6.4 Noninvasive and Minimally Invasive Monitoring Devices ............ 49

3.7 TREATMENT ................ 50

3.7.1 Lifestyle Measures 50

3.7.2 Insulin ................... 51

3.7.3 Oral Antidiabetic Drugs .. 51

3.7.4 Injectable Antidiabetic Drugs ........ 52

3.8 DRUG DELIVERY ......... 52

3.8.1 Insulin Syringes ..... 52

3.8.2 Insulin Pens ........... 52

3.8.3 Insulin Pumps ....... 52

3.8.4 Inhaled Insulin ...... 53

3.8.5 Insulin Patches ...... 53

3.9 EMERGING TECHNOLOGIES ... 54

3.10 MARKET OVERVIEW . 55

3.11 MARKET ANALYSIS BY SEGMENT ..... 57

3.12 TREND ANALYSIS AND FORECAST BY SEGMENT ...... 61

3.13 MARKET DRIVERS AND LIMITERS ..... 64

3.13.1 Market Drivers .... 64

3.13.2 Market Limiters ... 65

3.14 COMPETITIVE ANALYSIS ..... 67

DIABETES IN THE U.S. ......77

4.1 DIABETES PREVALENCE ........ 77

4.2 DIABETES INCIDENCE . 80

4.3 DIABETES DEMOGRAPHICS .... 82

4.4 OBESITY PREVALENCE .......... 85

TRADITIONAL BLOOD GLUCOSE METERS ...............89

5.1 INTRODUCTION ........... 89

5.2 MARKET ANALYSIS AND FORECAST ... 90

5.2.1 Total Blood Glucose Monitoring Market .............. 90

5.2.2 Total Traditional Blood Glucose Meter Market ... 93

5.2.3 Professional Traditional Blood Glucose Meter Market .. 96

5.2.4 Personal Traditional Blood Glucose Meter Market ........ 99

5.3 MARKET DRIVERS AND LIMITERS ..... 102

5.3.1 Market Drivers .... 102

5.3.2 Market Limiters ... 103

5.4 COMPETITIVE ANALYSIS ..... 105

CONTINUOUS GLUCOSE MONITORING SYSTEMS 108

6.1 INTRODUCTION ......... 108

6.2 MARKET ANALYSIS AND FORECAST . 109

6.2.1 Total Blood Glucose Monitoring Market ............ 109

6.2.2 Continuous Glucose Monitoring System Market 112

6.3 MARKET DRIVERS AND LIMITERS ..... 114

6.3.1 Market Drivers .... 114

6.3.2 Market Limiters ... 115

6.4 COMPETITIVE ANALYSIS ..... 118

BLOOD GLUCOSE TEST STRIPS ...........120

7.1 INTRODUCTION ......... 120

7.2 MARKET ANALYSIS AND FORECAST . 121

7.2.1 Total Blood Glucose Monitoring Market ............ 121

7.2.2 Diabetic Population Using Blood Glucose Monitor Test Strips .. 124

7.2.3 Total Blood Glucose Test Strip Market .............. 125

7.2.4 Professional Blood Glucose Test Strip Market ... 127

7.2.5 Personal Blood Glucose Test Strip Market ........ 129

7.3 MARKET DRIVERS AND LIMITERS ..... 131

7.3.1 Market Drivers .... 131

7.3.2 Market Limiters ... 132

7.4 COMPETITIVE ANALYSIS ..... 134

LANCETS AND LANCING DEVICES .....137

8.1 INTRODUCTION ......... 137

8.2 MARKET ANALYSIS AND FORECAST . 138

8.2.1 Total Blood Glucose Monitoring Market ............ 138

8.2.2 Total Lancet and Lancing Device Market .......... 140

8.2.3 Professional Lancet and Lancing Device Market .......... 143

8.2.4 Personal Lancet and Lancing Device Market .... 146

8.3 MARKET DRIVERS AND LIMITERS ..... 149

8.3.1 Market Drivers .... 149

8.3.2 Market Limiters ... 150

8.4 COMPETITIVE ANALYSIS ..... 152

INSULIN .......155

9.1 INTRODUCTION ......... 155

9.1.1 Insulin Types ....... 155

9.2 MARKET ANALYSIS AND FORECAST . 159

9.2.1 Total Insulin Market ...... 159

9.2.2 Rapid-Acting Insulin Analogs ...... 163

9.2.3 Regular and Intermediate-Acting Human Insulin .......... 165

9.2.4 Long-Acting Insulin Analog ......... 167

9.2.5 Insulin Mixtures .. 169

9.3 MARKET DRIVERS AND LIMITERS ..... 171

9.3.1 Market Drivers .... 171

9.3.2 Market Limiters ... 172

9.4 COMPETITIVE ANALYSIS ..... 174

INSULIN SYRINGES .........177

10.1 INTRODUCTION ....... 177

10.2 MARKET ANALYSIS AND FORECAST ...................... 178

10.2.1 Total Insulin Syringe Market ..... 178

10.2.2 Professional Insulin Syringe Market ................ 180

10.2.3 Personal Insulin Syringe Market ...................... 182

10.3 MARKET DRIVERS AND LIMITERS ... 184

10.3.1 Market Drivers .. 184

10.3.2 Market Limiters . 185

10.4 COMPETITIVE ANALYSIS ... 187

INSULIN PENS ...................190

11.1 INTRODUCTION ....... 190

11.2 MARKET ANALYSIS AND FORECAST ...................... 191

11.3 MARKET DRIVERS AND LIMITERS ... 193

11.3.1 Market Drivers .. 193

11.3.2 Market Limiters . 194

11.4 COMPETITIVE ANALYSIS ... 196

INSULIN PUMPS ................198

12.1 INTRODUCTION ....... 198

12.2 MARKET ANALYSIS AND FORECAST ...................... 200

12.2.1 Total Insulin Pump and Insulin Pump Infusion Set Market ....... 200

12.2.2 Insulin Pump Market ... 202

12.2.3 Insulin Pump Infusion Set Market ..................... 204

12.3 MARKET DRIVERS AND LIMITERS ... 206

12.3.1 Market Drivers .. 206

12.3.2 Market Limiters . 208

12.4 COMPETITIVE ANALYSIS ... 210

ORAL ANTIDIABETIC DRUGS .212

13.1 INTRODUCTION ....... 212

13.2 MARKET ANALYSIS AND FORECAST ...................... 223

13.2.1 Total Oral Antidiabetic Drug Market ............... 223

13.2.1.1 Unit Analysis 223

13.2.1.2 Price Analysis .........224

13.2.1.3 Market Analysis ......226

13.2.2 Alpha-Glucosidase Inhibitors .... 230

13.2.3 Biguanides ........ 233

13.2.3.1 Total Biguanide Market ........233

13.2.3.2 Brand Name Biguanide Market ...................236

13.2.3.3 Generic Biguanide Market ...238

13.2.4 DPP-IV Inhibitors ........ 240

13.2.5 Sulfonylureas .... 243

13.2.5.1 Total Sulfonylurea Market ....243

13.2.5.2 Brand Name Sulfonylurea Market ...............246

13.2.5.3 Generic Sulfonylurea Market ......................248

13.2.6 Meglitinides ...... 250

13.2.7 Thiazolidinediones ....... 253

13.2.8 Single Pill Combinations ........... 256

13.3 MARKET DRIVERS AND LIMITERS ... 259

13.3.1 Market Drivers .. 259

13.3.2 Market Limiters . 261

13.4 COMPETITIVE ANALYSIS ... 263

INJECTABLE ANTIDIABETIC DRUGS .268

14.1 INTRODUCTION ....... 268

14.2 MARKET ANALYSIS AND FORECAST ...................... 272

14.2.1 Total Injectable Antidiabetic Drug Market ....... 272

14.2.1.1 Unit Analysis 272

14.2.1.2 Price Analysis .........273

14.2.1.3 Market Analysis ......274

14.2.2 GLP-1 Receptor Agonists .......... 278

14.2.3 Amylinomimetics .......... 281

14.3 MARKET DRIVERS AND LIMITERS ... 283

14.3.1 Market Drivers .. 283

14.3.2 Market Limiters . 284

14.4 COMPETITIVE ANALYSIS ... 286

ABBREVIATIONS ..............288

LIST OF FIGURES

EXECUTIVE SUMMARY ........... 18

RESEARCH METHODOLOGY ... 29

OVERVIEW OF DIABETES ....... 40

Figure 3-1: Major Types of Diabetes and Related Pathologies ..... 42

Figure 3-2: Risk Factors Associated with Type 1 and Type 2 Diabetes ............... 46

Figure 3-3: Signs and Symptoms Associated with Type 1 and Type 2 Diabetes ... 47

Figure 3-4: Blood Glucose Ranges Recommended by the American Diabetes

Association (ADA), U.S., 2009 ...................... 49

Figure 3-5: Total Diabetes Diagnosis, Treatment and Drug Delivery Market by

Segment, U.S., 2006 - 2016 .... 58

Figure 3-6: Trend Analysis, Growth Rates by Market Segment, U.S. Market for

Diabetics Diagnosis, Treatment and Drug Delivery, 2006 - 2016 .................... 62

Figure 3-7: Drivers and Limiters in the U.S. Market for Diabetes Diagnosis,

Treatment and Drug Delivery, 2009 ............... 66

Figure 3-8: Leading Competitors in the Diabetes Diagnosis, Monitoring,

Treatment and Drug Delivery Market, U.S., 2006 - 2016 (Part 1) ................... 70

Figure 3-9: Leading Competitors in the Diabetes Diagnosis, Monitoring,

Treatment and Drug Delivery Market, U.S., 2006 - 2016 (Part 2) ................... 71

Figure 3-10: Leading Competitors in the Devices Segment of the Total Market

for Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2009 .................. 73

Figure 3-11: Leading Competitors in the Insulin and Antidiabetic Drug Segment

of the Total Market for Diabetes Diagnosis, Treatment and Drug Delivery,

U.S., 2009 ..... 75

DIABETES IN THE U.S. ............ 77

Figure 4-1: Total Prevalence of Diabetes Both Diagnosed and Undiagnosed,

Adults Aged 18 - 79, U.S., 2006 - 2016 ......... 78

Figure 4-2: Incidence of Diabetes in Adults Aged 18 - 79, U.S., 2006 - 2016 .... 80

Figure 4-3: Percentage of Population Diagnosed with Diabetes by Race and Sex,

U.S., 2006 - 2016 ..... 83

Figure 4-4: Obesity Prevalence in Adults by State, Alabama to Mississippi,

U.S., 2008 (Part 1) .... 86

Figure 4-5: Obesity Prevalence in Adults by State, Missouri to Wyoming, U.S.,

2008 (Part 2) . 87

TRADITIONAL BLOOD GLUCOSE METERS .. 89

Figure 5-1: Blood Glucose Ranges Recommended by the American Diabetes

Association (ADA), U.S., 2009 ...................... 89

Figure 5-2: Total Blood Glucose Monitoring Market, U.S., 2006 - 2016 ............ 91

Figure 5-3: Total Traditional Blood Glucose Meter Market by Segment, U.S.,

2006 - 2016 ... 94

Figure 5-4: Professional Traditional Blood Glucose Meter Market, U.S., 2006 -

2016 .............. 97

Figure 5-5: Personal Traditional Blood Glucose Meter Market, U.S., 2006 -

2016 ............ 100

Figure 5-6: Drivers and Limiters, Traditional Blood Glucose Meter Market,

U.S., 2009 ... 104

Figure 5-7: Leading Competitors in the Traditional Blood Glucose Meter

Market, U.S., 2009 . 106

CONTINUOUS GLUCOSE MONITORING SYSTEMS 108

Figure 6-1: Total Blood Glucose Monitoring Market, U.S., 2006 - 2016 .......... 110

Figure 6-2: Continuous Glucose Monitoring System Market, U.S., 2006 - 2016112

Figure 6-3: Drivers and Limiters, Continuous Glucose Monitoring System

Market, U.S., 2009 . 117

Figure 6-4: Leading Competitors in the Continuous Glucose Monitoring System

Market, U.S., 2009 . 118

BLOOD GLUCOSE TEST STRIPS ................... 120

Figure 7-1: Total Blood Glucose Monitoring Market, U.S., 2006 - 2016 .......... 122

Figure 7-2: Diabetic Population Using Blood Glucose Monitor Test Strips, U.S.,

2006 - 2016 . 124

Figure 7-3: Total Blood Glucose Test Strip Market by Segment, U.S., 2006 -

2016 ............ 125

Figure 7-4: Professional Blood Glucose Test Strip Market by Segment, U.S.,

2006 - 2016 . 127

Figure 7-5: Personal Blood Glucose Test Strip Market by Segment, U.S., 2006 -

2016 ............ 129

Figure 7-6: Drivers and Limiters, Blood Glucose Test Strips Market, U.S., 2009133

Figure 7-7: Leading Competitors in the Blood Glucose Test Strips Market, U.S.,

2009 ............ 135

LANCETS AND LANCING DEVICES ............. 137

Figure 8-1: Total Blood Glucose Monitoring Market, U.S., 2006 - 2016 .......... 138

Figure 8-2: Total Market for Lancets and Lancing Devices by Segment, U.S.,

2006 - 2016 . 141

Figure 8-3: Professional Market for Lancets and Lancing Devices, U.S., 2006 -

2016 ............ 144

Figure 8-4: Personal Market for Lancets and Lancing Devices, U.S., 2006 -

2016 ............ 147

Figure 8-5: Drivers and Limiters, Lancet and Lancing Device Market, U.S.,

2009 ............ 151

Figure 8-6: Leading Competitors in the Lancet and Lancing Device Market,

U.S., 2009 ... 153

INSULIN ......... 155

Figure 9-1: Onset, Peak and Duration of Insulin Types, U.S., 2009 .................. 156

Figure 9-2: Brand Name Insulin, U.S., 2009 .... 158

Figure 9-3: Total Market for Insulin by Segment, U.S., 2006 - 2016 ................ 161

Figure 9-4: Rapid-Acting Insulin Analog Market, U.S., 2006 - 2016 ................ 163

Figure 9-5: Regular and Intermediate-Acting Human Insulin Market, U.S., 2006

- 2016 ......... 165

Figure 9-6: Long-Acting Insulin Analog Market, U.S., 2006 - 2016 ................. 167

Figure 9-7: Insulin Mixture Market, U.S., 2006 - 2016 ............. 169

Figure 9-8: Drivers and Limiters for the Insulin Market, U.S., 2009 ................. 173

Figure 9-9: Leading Competitors in the Insulin Market, U.S., 2009 .................. 175

INSULIN SYRINGES . 177

Figure 10-1: Total Market for Insulin Syringes by Segment, U.S., 2006 - 2016 . 178

Figure 10-2: Professional Market for Insulin Syringes, U.S., 2006 - 2016 ......... 180

Figure 10-3: Personal Market for Insulin Syringes, U.S., 2006 - 2016 ............... 182

Figure 10-4: Drivers and Limiters for the Insulin Syringe Market, U.S., 2009... 186

Figure 10-5: Leading Competitors in the Total Insulin Syringe Market, U.S.,

2009 ............ 188

INSULIN PENS .......... 190

Figure 11-1: Insulin Pens Market, U.S., 2006 - 2016 ... 191

Figure 11-2: Drivers and Limiters for the Insulin Pen Market, U.S., 2009......... 195

Figure 11-3: Leading Competitors in the Insulin Pen Market, U.S., 2009 .......... 196

INSULIN PUMPS ....... 198

Figure 12-1: Total Market for Insulin Pumps and Insulin Pump Infusion Sets by

Segment, U.S., 2006 - 2016 .. 200

Figure 12-2: Insulin Pump Market, U.S., 2006 - 2016 . 202

Figure 12-3: Insulin Pump Infusion Set Market, U.S., 2006 - 2016 .................. 204

Figure 12-4: Drivers and Limiters for the Insulin Pump Market, U.S., 2009...... 209

Figure 12-5: Leading Competitors in the Insulin Pump Market, U.S., 2009 ....... 210

ORAL ANTIDIABETIC DRUGS ...................... 212

Figure 13-1: Oral Antidiabetic Drug Overviews, U.S., 2009 ...... 214

Figure 13-2: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 1)................ 215

Figure 13-3: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 2)................ 216

Figure 13-4: Oral Antidiabetic Drug Indications, U.S., 2009 (Part 3)................ 217

Figure 13-5: Oral Antidiabetic Drugs, U.S., 2009 (Part 1) ......... 218

Figure 13-6: Oral Antidiabetic Drugs, U.S., 2009 (Part 2) ......... 219

Figure 13-7: Adult Doses of Oral Antidiabetic Drugs, U.S., 2009 (Part 1) ........ 220

Figure 13-8: Adult Doses of Oral Antidiabetic Drugs, U.S., 2009 (Part 2) ........ 221

Figure 13-9: Oral Antidiabetic Drugs FDA Approval and Patent Expiry, U.S.,

2009 (Part 1) .......... 222

Figure 13-10: Oral Antidiabetic Drug Units, U.S., 2009 ............ 223

Figure 13-11: Oral Antidiabetic Drug Price Indices, U.S., 2009 . 225

Figure 13-12: Total Oral Antidiabetic Drug Market by Segment, U.S., 2006 -

2016 ............ 227

Figure 13-13: Alpha-Glucosidase Inhibitor Market, U.S., 2006 - 2016 ............. 231

Figure 13-14: Total Biguanide Market by Segment, U.S., 2006 - 2016 ............. 234

Figure 13-15: Brand-Name Biguanide Market, U.S., 2006 - 2016..................... 236

Figure 13-16: Generic Biguanide Market, U.S., 2006 - 2016 ..... 238

Figure 13-17: DPP-IV Inhibitor Market, U.S., 2006 - 2016 ....... 241

Figure 13-18: Total Sulfonylurea Market by Segment, U.S., 2006 - 2016 ......... 244

Figure 13-19: Brand-Name Sulfonylurea Market, U.S., 2006 - 2016................. 246

Figure 13-20: Generic Sulfonylurea Market, U.S., 2006 - 2016 . 248

Figure 13-21: Meglitinide Market, U.S., 2006 - 2016 . 251

Figure 13-22: Thiazolidinedione (TZD) Market, U.S., 2006 - 2016 .................. 254

Figure 13-23: Single Pill Combination Market, U.S., 2006 - 2016.................... 257

Figure 13-24: Drivers and Limiters for the Oral Antidiabetic Drug Market, U.S.,

2009 ............ 262

Figure 13-25: Leading Competitors in the Oral Antidiabetic Drug Market, U.S.,

2009 ............ 266

INJECTABLE ANTIDIABETIC DRUGS .......... 268

Figure 14-1: Injectable Antidiabetic Drug Indications, U.S., 2009 .................... 270

Figure 14-2: Injectable Antidiabetic Drugs, U.S., 2009 ............. 270

Figure 14-3: Injectable Antidiabetic Drugs, U.S., 2009 ............. 271

Figure 14-4: Injectable Antidiabetic Drugs, FDA Approval and Patent Expiry,

U.S., 2009 ... 271

Figure 14-5: Injectable Antidiabetic Drug Units, U.S., 2009 ...... 272

Figure 14-6: Injectable Antidiabetic Drug Price Indices, U.S., 2009 ................. 273

Figure 14-7: Total Injectable Antidiabetic Drug Market by Segment, U.S., 2006

- 2016 ......... 275

Figure 14-8: GLP-1 Receptor Agonist Market, U.S., 2006 - 2016..................... 279

Figure 14-9: Amylinomimetic Market, U.S., 2006 - 2016 .......... 281

Figure 14-10: Drivers and Limiters for the Injectable Antidiabetic Drug Market,

U.S., 2009 ... 285

Figure 14-11: Leading Competitors in the Injectable Antidiabetic Drug Market,

U.S., 2009 ... 287

ABBREVIATIONS ..... 288

LIST OF CHARTS

EXECUTIVE SUMMARY ........... 18

Chart 1-1: Market for Diabetes Diagnosis, Treatment and Drug Delivery, U.S.,

2006 - 2016 ... 18

Chart 1-2: Fastest Growing Market Segments, Diabetes Diagnosis, Treatment and

Drug Delivery Market, U.S., 2006 - 2016 ...... 19

Chart 1-3 : Blood Glucose Test Strips as a Proportion of the Total Blood Glucose

Monitoring Market, U.S., 2009 ...................... 20

Chart 1-4: Prevalence of Diabetes Both Diagnosed and Undiagnosed, Adults

Aged 18 - 79, U.S., 2006 - 2016 .................... 21

Chart 1-5: Average Onset, Peak and Duration of Insulin Types Used in the U.S.,

2009 .............. 22

Chart 1-6: Total Market for Insulin Syringes by Segment, U.S., 2006 - 2016....... 23

Chart 1-7: Insulin Pump Market by Segment, U.S., 2006 - 2016 .. 24

Chart 1-8: Price Index Comparison, Oral Antidiabetic Drugs, U.S., 2009 ............ 25

Chart 1-9: Market Growth Analysis, Oral Antidiabetic Drugs, U.S., 2009........... 26

Chart 1-10: Leading Competitors in the Combined Market for Diabetes Devices,

U.S., 2009 ..... 27

Chart 1-11: Leading Competitors in the Combined Market for Insulin and

Antidiabetic Drugs, U.S., 2009 ...................... 28

RESEARCH METHODOLOGY ... 29

OVERVIEW OF DIABETES ....... 40

Chart 3-1: Total Diabetes Diagnosis, Treatment and Drug Delivery Market, U.S.,

2006 - 2016 ... 56

Chart 3-2: Total Diabetes Diagnosis, Monitoring, Treatment and Drug Delivery

Market by Segment, U.S., 2009 ...................... 59

Chart 3-3: Total Diabetes Diagnosis, Monitoring, Treatment and Drug Delivery

Market by Segment, U.S., 2016 ...................... 60

Chart 3-4: Fastest Growing Market Segments, Diabetes Diagnosis, Treatment

and Drug Delivery Market, U.S., 2006 - 2016 .......... 63

Chart 3-5: Leading Competitors in the Total Diabetes Diagnosis, Monitoring,

Treatment and Drug Delivery Market, U.S., 2006 - 2016 ......... 72

Chart 3-6: Leading Competitors in the Devices Segment of the Total Market for

Diabetes Diagnosis, Treatment and Drug Delivery, U.S., 2009 . 74

Chart 3-7: Leading Competitors in the Insulin and Antidiabetic Drug Segment of

the Total Market for Diabetes Diagnosis, Treatment and Drug Delivery, U.S.,

2009 .............. 76

DIABETES IN THE U.S. ............ 77

Chart 4-1: Prevalence of Diabetes Both Diagnosed and Undiagnosed, Adults

Aged 18 - 79, U.S., 2006 - 2016 .................... 79

Chart 4-2: Incidence of Diabetes in Adults Aged 18 - 79, U.S., 2006 - 2016 ...... 81

Chart 4-3: Percentage of Population Diagnosed with Diabetes by Race and Sex,

U.S., 2009 ..... 84

Chart 4-4: Obesity Prevalence in Adults by State, U.S., 2008 ...... 88

TRADITIONAL BLOOD GLUCOSE METERS .. 89

Chart 5-1: Traditional Blood Glucose Monitors as a Proportion of the Total

Blood Glucose Monitoring Market, U.S., 2009 .......... 92

Chart 5-2: Total Traditional Blood Glucose Meter Market by Segment, U.S.,

2006 - 2016 ... 95

Chart 5-3: Professional Traditional Blood Glucose Meter Market, U.S., 2006 -

2016 .............. 98

Chart 5-4: Personal Traditional Blood Glucose Meter Market Segmented by

Price Range, U.S., 2009 .......... 99

Chart 5-5: Personal Traditional Blood Glucose Meter Market, U.S., 2006 - 2016101

Chart 5-6: Leading Competitors in the Blood Glucose Monitoring Device

Market, U.S., 2009 . 107

CONTINUOUS GLUCOSE MONITORING SYSTEMS 108

Chart 6-1: Continuous Glucose Monitoring Systems as a Proportion of the Total

Blood Glucose Monitoring Market, U.S., 2009 ........ 111

Chart 6-2: Continuous Glucose Monitoring System Market, U.S., 2006 - 2016 . 113

Chart 6-3: Leading Competitors in the Continuous Glucose Monitoring System

Market, U.S., 2009 . 119

BLOOD GLUCOSE TEST STRIPS ................... 120

Chart 7-1: Blood Glucose Test Strips as a Proportion of the Total Blood Glucose

Monitoring Market, U.S., 2009 .................... 123

Chart 7-2: Total Blood Glucose Test Strip Market by Segment, U.S., 2006 -

2016 ............ 126

Chart 7-3: Professional Blood Glucose Test Strip Market by Segment, U.S.,

2006 - 2016 . 128

Chart 7-4: Personal Blood Glucose Test Strip Market by Segment, U.S., 2006 -

2016 ............ 130

Chart 7-5: Leading Competitors in the Blood Glucose Test Strips Market, U.S.,

2009 ............ 136

LANCETS AND LANCING DEVICES ............. 137

Chart 8-1: Lancets and Lancing Devices as a Proportion of the Total Blood

Glucose Monitoring Market, U.S., 2009 ....... 139

Chart 8-2: Total Market for Lancets and Lancing Devices by Segment, U.S.,

2006 - 2016 . 142

Chart 8-3: Professional Market for Lancets and Lancing Devices, U.S., 2006 -

2016 ............ 145

Chart 8-4: Personal Market for Lancets and Lancing Devices, U.S., 2006 - 2016148

Chart 8-5: Leading Competitors in the Lancet and Lancing Device Market, U.S.,

2009 ............ 154

INSULIN ......... 155

Chart 9-1: Onset, Peak and Duration of Insulin Types, U.S., 2009 .................... 157

Chart 9-2: Total Market for Insulin by Segment, U.S., 2006 - 2016.................. 162

Chart 9-3: Rapid-Acting Insulin Analog Market, U.S., 2006 - 2016 ................. 164

Chart 9-4: Regular and Intermediate-Acting Human Insulin Market, U.S., 2006 -

2016 ............ 166

Chart 9-5: Long-Acting Insulin Analog Market, U.S., 2006 - 2016................... 168

Chart 9-6: Insulin Mixture Market, U.S., 2006 - 2016 . 170

Chart 9-7: Leading Competitors in the Insulin Market, U.S., 2009.................... 176

INSULIN SYRINGES . 177

Chart 10-1: Total Market for Insulin Syringes by Segment, U.S., 2006 - 2016.. 179

Chart 10-2: Professional Market for Insulin Syringes, U.S., 2006 - 2016.......... 181

Chart 10-3: Personal Market for Insulin Syringes, U.S., 2006 - 2016 ............... 183

Chart 10-4: Leading Competitors in the Total Insulin Syringe Market, U.S.,

2009 ............ 189

INSULIN PENS .......... 190

Chart 11-1: Insulin Pen Market, U.S., 2006 - 2016 ..... 192

Chart 11-2: Leading Competitors in the Insulin Pen Market, U.S., 2009 ........... 197

INSULIN PUMPS ....... 198

Chart 12-1: Total Market for Insulin Pumps and Insulin Pump Infusion Sets by

Segment, U.S., 2006 - 2016 .. 201

Chart 12-2: Insulin Pump Market, U.S., 2006 - 2016 .. 203

Chart 12-3: Insulin Pump Infusion Set Market, U.S., 2006 - 2016 .................... 205

Chart 12-4: Leading Competitors in the Insulin Pump Market, U.S., 2009 ........ 211

ORAL ANTIDIABETIC DRUGS ...................... 212

Chart 13-1: Total Oral Antidiabetic Drug Market by Segment, U.S., 2006 - 2016228

Chart 13-2: Total Oral Antidiabetic Drug Market by Segment, U.S., 2009 ........ 229

Chart 13-3: Alpha-Glucosidase Inhibitor Market, U.S., 2006 - 2016 ................ 232

Chart 13-4: Total Biguanide Market by Segment, U.S., 2006 - 2016 ................ 235

Chart 13-5: Brand Name Biguanide Market, U.S., 2006 - 2016 . 237

Chart 13-6: Generic Biguanide Market, U.S., 2006 - 2016 ........ 239

Chart 13-7: DPP-IV Inhibitor Market, U.S., 2006 - 2016 .......... 242

Chart 13-8: Total Sulfonylurea Market by Segment, U.S., 2006 - 2016 ............ 245

Chart 13-9: Brand Name Sulfonylurea Market, U.S., 2006 - 2016 .................... 247

Chart 13-10: Generic Sulfonylurea Market, U.S., 2006 - 2016 .. 249

Chart 13-11: Meglitinide Market, U.S., 2006 - 2016 ... 252

Chart 13-12: Thiazolidinedione (TZD) Market, U.S., 2006 - 2016.................... 255

Chart 13-13: Single Pill Combination Market, U.S., 2006 - 2016 ..................... 258

Chart 13-14: Leading Competitors in the Oral Antidiabetic Drug Market, U.S.,

2009 ............ 267

INJECTABLE ANTIDIABETIC DRUGS .......... 268

Chart 14-1: Total Injectable Antidiabetic Drug Market by Segment, U.S., 2006 -

2016 ............ 276

Chart 14-2: Total Injectable Antidiabetic Drug Market by Segment, U.S., 2009 277

Chart 14-3: GLP-1 Receptor Agonist Market, U.S., 2006 - 2016 ...................... 280

Chart 14-4: Amylinomimetic Market, U.S., 2006 - 2016 ........... 282

Chart 14-5: Leading Competitors in the Injectable Antidiabetic Drug Market,

U.S., 2009 ... 286

ABBREVIATIONS ..... 288

To order this report:

Drug Delivery Technology Industry: U.S. Market for Diabetes Monitoring, Treatment and Drug Delivery 2010

More Market Research Report

Contact: Nicolas Bombourg Reportlinker Email: nbo@reportlinker.com US: (805)652-2626 Intl: +1 805-652-2626

SOURCE Reportlinker
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Hot Fitness Concept Comes to Atlanta
S
Medical Specialists Petition Congress to Preserve ...